Please login to the form below

Not currently logged in

HR+/HER2- metastatic disease

This page shows the latest HR+/HER2- metastatic disease news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer

Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer

Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%, Gilead reported. ... As patients with HR+/HER2- metastatic breast

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...